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Restoring immune tolerance in
neuromyelitis optica
Part I
ABSTRACT
Neuromyelitis optica (NMO) and spectrum disorder (NMO/SD) represent a vexing process and its
clinical variants appear to have at their pathogenic core the loss of immune tolerance to the
aquaporin-4 water channel protein. This process results in a characteristic pattern of astrocyte
dysfunction, loss, and demyelination that predominantly affects the spinal cord and optic nerves.
Although several empirical therapies are currently used in the treatment of NMO/SD, none has
been proven effective in prospective, adequately powered, randomized trials. Furthermore, most
of the current therapies subject patients to long-term immunologic suppression that can cause
serious infections and development of cancers. The following is the first of a 2-part description
of several key immune mechanisms in NMO/SD that might be amenable to therapeutic restoration
of immune tolerance. It is intended to provide a roadmap for how potential immune tolerance
restorative techniques might be applied to patients with NMO/SD. This initial installment provides
a background rationale underlying attempts at immune tolerization. It provides specific examples
of innovative approaches that have emerged recently as a consequence of technical advances. In
several autoimmune diseases, these strategies have been reduced to practice. Therefore, in the-
ory, the identification of aquaporin-4 as the dominant autoantigen makes NMO/SD an ideal can-
didate for the development of tolerizing therapies or cures for this increasingly recognized
disease. Neurol Neuroimmunol Neuroinflamm 2016;3:e276; doi: 10.1212/NXI.0000000000000276
GLOSSARY
APC 5 antigen-presenting cell; AQP4 5 aquaporin 4; CAR 5 chimeric antigen receptor; DC 5 dendritic cell; EAE 5 exper-
imental autoimmune encephalomyelitis; HLA 5 human leukocyte antigen; IgG 5 immunoglobulin G; IL 5 interleukin; MHC 5
major histocompatibility complex; NMO 5 neuromyelitis optica; PBMC 5 peripheral blood mononuclear cell; scFv 5 single
chain variable fragment; SD 5 spectrum disorder; T1D 5 type 1 diabetes; TcR 5 T cell receptor; Treg 5 regulatory T cell.
RATIONALE FOR TOLERIZATION IN NMO Neuromyelitis optica (NMO) or NMO spectrum disorder
(NMO/SD) represents a potentially devastating neuroinflammatory disease in which the spinal cord and optic
nerve(s) preferentially undergo astrocyte damage and demyelination.1 Recent investigations into its pathogen-
esis have demonstrated NMO/SD to be distinct from multiple sclerosis (MS) (figure 1).2 Identification of
pathogenic anti-aquaporin 4 (anti-AQP4) antibody (NMO–immunoglobulin G [IgG])3 in context of other
clinical characteristics now secures a diagnosis in seropositive disease.
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Despite substantial advances in understanding
NMO/SD, no existing regimen has been unambigu-
ously proven to modify disease course, induce perma-
nent remission, or restore lost neurologic function in
adequately powered, prospective clinical trials. Con-
tinuing reliance on nonspecific agents, including cor-
ticosteroids, azathioprine, mycophenolate, and B cell
depletion4,5 exposes patients to potentially serious
adverse effects. Absence of animal models with com-
plete fidelity to human NMO/SD has been a histori-
cal impediment to novel therapies.
Improved diagnosis has facilitated greater focus
on developing specific therapies. Antigen-specific ap-
proaches could restore immune tolerance to AQP4
and minimize epitope spreading. In NMO/SD, dys-
functions in checkpoints governing immune cell devel-
opment contribute to autoreactive immunity (figure 2).
Considerable progress has been made in tolerizing
strategies used to treat allergies,6 transplant and graft
rejection,7 and drug hypersensitivity.8 In theory,
antigen-targeted approaches spare normal immune
functions. To date, similar strategies have yielded only
limited success in other autoimmune diseases, such as
type 1 diabetes (T1D),9 relapsing-remitting MS,10 and
inflammatory bowel disease.11 Results thus far support
the general concept that inhibition of antigen-specific
T cell and/or B cell responses is achievable and may be
durable. However, in some experimental models, tol-
erization strategies have worsened disease,12 perhaps
because of uncertain disease etiology. Hence, in the
specific context of NMO/SD, tolerization might have
distinct advantages.
The Guthy-Jackson Charitable Foundation con-
vened a meeting of experts in development of
antigen-specific therapy. Key goals of this meeting
were to ascertain the state-of-the-art in immune toler-
ization as it might be applied to NMO/SD and to cat-
alyze innovative thinking. The following discussion
considers specific opportunities and challenges to
apply tolerization therapy to solve NMO/SD.
POTENTIAL STRATEGIES FOR TOLERIZATION
IN NMO Inverse DNA vaccination. Dolgin13 and
Steinman14 have built on principles of classic desen-
sitization originating with Jenner. While traditional
vaccines induce immune responses to specific anti-
gens, inverse vaccines promote immune tolerance.
Diseases in which a known antigen underlies the
pathophysiology would in theory represent the most
promising candidates for tolerizing therapies. Thus,
seropositive NMO/SD should be ideal for antigen-
specific therapy, as autoimmune responses to AQP4
are believed to be fundamental to the disease.15–17 In
clinical trials, pathogenic vs tolerogenic immune
responses of T and B cells would necessarily be
monitored. Other diseases with similarly implicated
autoantigens include myasthenia gravis (acetylcholine
receptor), Graves disease (thyrotropin receptor and
thyroglobulin), and T1D (multiple insulin granule
antigens).18
Inverse vaccination with DNA encoding proinsu-
lin to reinforce tolerogenic immune checkpoints has
been evaluated in patients in an early-phase clinical
trial in T1D.18,19 The results suggest that immune
Figure 1 Integrative model of NMO/SD pathogenesis
Distinct stages of disease are illustrated as relative temporal and spatial comparators in NMO/SD progression. Note that over the course of disease pro-
gression and demyelination, additional autoantigens may be revealed and/or recognized, potentially resulting in antigen spreading and expansion/compound-
ing of autoreactivity. A 5 astrocyte (AQP4-expressing cells that support neuronal viability and function); AQP4 5 aquaporin 4; B 5 B lymphocyte; BBB 5
blood-brain barrier; E5 eosinophil; M5monocyte/macrophage; N5 neuron; NK5 natural killer cell; NMO/SD5 neuromyelitis optica/spectrum disorder; P5
polymorphonuclear leukocyte (neutrophil); PER 5 periphery; T 5 T lymphocyte.
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tolerance to proinsulin can be induced (p , 0.026).
The study revealed an inverse relationship between
antigen-restricted CD81 T cells and serum proinsulin
levels.18 A similar strategy has enabled proof-of-principle
of altered responses to myelin basic protein in patients
with MS.20,21 Although such approaches are attractive,
relevant antigenic targets likely differ among patients
and may change over time. For example, myelin oligo-
dendrocyte glycoprotein may drive unique pathogenesis
in NMO/SD and require specific tolerization strategies.
Moreover, epitopes may differ in peptides as compared
to parent proteins, and lipid or carbohydrate modifica-
tion may influence presentation.
Inverse DNA vaccination targeting tolerization
against AQP4 immunoreactivity has also been exam-
ined in experimental models of NMO/SD. A plasmid
encoding AQP4 attenuated T and B cell responses spe-
cifically to this antigen, attesting to antigen specificity
of this strategy (unpublished observations). In NMO/
SD, clinical trials may be designed based on one or
more diagnostic biomarker(s) of NMO-IgG seroposi-
tivity. In this approach, a diagnostic biomarker(s) is
used as a surrogate of therapeutic efficacy and durability
and serves as an outcome measure. This scenario ap-
proaches an idealized situation in which biomarkers
are both the principal diagnostic gating targets and
the major pathogenic factor(s).
Antiautoreactive T cell vaccines. Roles played by autor-
eactive T cells in mediating autoimmunity have been
established in several animal models, and comple-
mented observations made in human disease.22 In
turn, therapeutic modulation of autoreactive T cell
frequency and/or function in autoimmune diseases
appears achievable.23 However, regulation of all
immune responses results from the “checks and bal-
ances” imposed by both effector and regulatory T cell
networks (figure 3). Thus, nonspecific depletion of
effector T cells could diminish immune surveillance,
leading to infections or cancer.24 Similarly, indiscrim-
inate activation or depletion of regulatory T cells
(Tregs) may also result in immune dysfunction. In
particular, Tregs are capable of limiting the frequency
and/or activity of individual autoreactive T cell clones
through recognition of their unique T cell receptor
(TcR) idiotypes.25 When T cells aberrantly recognize
Figure 2 Comparative milestones in T and B lymphocyte maturation
(A) T cell development. (B) B cell development. Each lineage is represented with distinguishing markers for corresponding stages, and where cell commitment
occurs. Arrows indicate potential points along the development pathway where immune tolerizing interventions might be targeted in neuromyelitis optica/
spectrum disorder. CAR5 chimeric antigen receptor; CD5 class designation marker; CLP5 common lymphoid precursor; DN5 double-negative thymocyte;
DP5 double-positive CD41/CD81 thymocyte; Ig5 immunoglobulin; ImmB5 immature B cell; ISP5 immature single-positive CD81 thymocyte; LPreB5 large
PreB; MatB 5mature B cell; PreB 5 pre-B cell receptor B cell; ProB 5 progenitor B cell; SP 5 single positive CD41 or CD81 thymocyte; SPreB 5 small PreB;
TcR 5 T cell receptor; Treg 5 regulatory T cell.
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self-antigens in an absence of adequate regulatory
counterbalance, autoimmune disease might result.26
In NMO/SD, the pathogenic antibody response is
dominated by class-switched IgG, indicating an
underlying AQP4-reactive T cell activity.27,28 In
addition, Th17 polarization of naive T cells leads to
the secretion of proinflammatory cytokines in relation
to target lesions, including interleukin (IL)-17A and
granulocyte macrophage–colony stimulating factor.29
Such a proinflammatory cytokine profile may
promote tissue destruction through recruitment of
granulocytes or other cells capable of antibody-
dependent cell cytotoxicity.
The observation that anti-idiotypic Tregs can arise
spontaneously and be associated with the resolution of
autoimmunity led to the concept of T cell vaccina-
tion.30,31 This strategy invokes multiple immune func-
tions that may mitigate autoimmune disease. For
example, induction of idiotype-restricted CD41/
CD251/FoxP31 Tregs, IL-10–secreting CD41 Tr1
cells, and CD81 cytotoxic T cells can result, each capable
of selectively targeting autoreactive T cells that express
the idiotype represented by the immunizing T cells.32
T cell–based vaccines typically use attenuated
autologous autoreactive effector T cells as immuno-
gens32 in an amplification strategy designed to target
and counteract autoreactive T cells. Theoretically,
this process should selectively deplete and/or func-
tionally attenuate pathogenic T cells carrying the cor-
responding idiotype. Restoring an adequate Treg
influence theoretically should mitigate tissue dysfunc-
tion. Clinical trials have suggested a therapeutic ben-
efit from T cell vaccination, with minimal side
effects.33 In this regard, proof-of-principle has been
demonstrated in several animal models.31 In addition,
therapeutic trials applying this strategy to MS, rheu-
matoid arthritis, and systemic lupus erythematosus–
associated nephritis have been undertaken. In some of
these conditions, a T cell–based vaccine approach has
demonstrated considerable promise.34–36
The manufacture of autologous T cell vaccines is
dependent first on identifying autoantigen-specific
T cells within the peripheral blood of that patient.
This goal is achieved by performing an epitope profil-
ing assay, using overlapping peptides comprising the
amino acid sequence of the target antigen. The assay
readout is based on the detection of proinflammatory
cytokines induced by immunodominant peptides
within the target antigen. This strategy thereby iden-
tifies peptides and the associated T cell responses
most relevant to the autoimmune disease in an
affected individual. Next, bulk T cell lines are
expanded in vitro from an autologous peripheral
blood sample against the selected peptides to provide
sufficient numbers of autoreactive T cells to meet
dosing requirements. These particular T cells are ali-
quoted and cryopreserved. On demand, a dose-
equivalent is thawed, formulated, and attenuated
by irradiation before subcutaneous administration.
Methods currently in use allow a single-cycle
Figure 3 Hypothesized cellular and molecular crosstalk influencing NMO/SD
(A) Theoretical proinflammatory interactions that arise from loss of immune tolerance, which may promote the onset or pro-
gression of neuromyelitis optica/spectrum disorder (NMO/SD). (B) Theoretical anti-inflammatory interactions that arise and
could be amenable to therapeutic intervention in restoring immune tolerance in NMO/SD. (Cellular) APC5 antigen-present-
ing cell; Bc5B cell; Tc5 T cell; (cell surface determinants) CD5 class designation; MHC5major histocompatibility complex;
(soluble) BAFF 5 B cell activating factor; IL 5 interleukin; IL-18BP 5 IL-18 binding protein; sIL-1R 5 soluble IL-1 receptor;
sTNFR 5 soluble tumor necrosis factor a receptor.
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manufacturing process from one blood collection to
be used to generate sufficient drug for at least 1 year
of treatment.
Considering the aggregate evidence, a compelling
case can be made for the critical role of T cells in
the pathogenesis of NMO/SD.29 It follows that
reestablishment of immune tolerance to AQP4
through vaccination with autologous, attenuated,
and idiotype-restricted T cells represents a promising
new approach to immunotherapy in this disease.
Dendritic cell vaccines. Dendritic cells (DCs) present
antigens to immune cells, including those with regula-
tory and autoreactive function, through major histo-
compatibility complex (MHC) class I and II
restriction. Normally, DCs present self-antigens but
do not drive autoreactive immune responses. Thus,
autoreactive T cells are inactivated or anergized
because of low MHC expression, inadequate
costimulation (e.g., inducing anergy), or tolerogenic
costimulation (e.g., PD-L1 [programed death ligand
1], IL-10, etc). In addition, DCs have important roles
in maintaining tolerance by promoting regulatory
cells, such as CD41 and CD81 Tregs, and IL-10–
producing regulatory B cells.37 Immature human DCs
are readily generated in the laboratory from blood
monocytes and can be engineered to maintain
tolerogenic phenotypes. Indeed, DC-based therapies
have now entered clinical trials focusing on NMO/SD
(ClinicalTrials.gov identifier: NCT02283671).
As a strategy for inducing immune tolerance in
T1D, DC administration has proven relatively safe.38–
42 Here, granulocyte macrophage–colony stimulating
factor/IL-4 was used to generate immature CD11c1
DCs from monocytes in vitro. Transition to a proin-
flammatory DC phenotype is concerning when DCs
are administered to human patients. To mitigate this
concern, immature DCs can be treated in vitro with
immunosuppressive agents such as corticosteroids, vita-
min D3, and/or IL-1043 before their use as tolerizing
vaccines. The resulting DCs exhibit durable tolerogenic
phenotypes that prolong organ allograft survival in
mice. Notably, this conditioning enhances the tolero-
genic properties of DCs44 and induces high-level IL-10
production, which inhibit activated Th1 and Th17
cells, induce Tregs, and suppress autoreactive B cell
functions. A related strategy involves loading of imma-
ture DCs with antisense oligonucleotides targeting key
costimulatory molecules such as CD40, CD80, or
CD86. Alternatively, viral vectors encoding immuno-
regulatory factors may potentiate tolerogenic DCs. Of
note, the maintenance of DC immaturity also allows
these cells to migrate into lymph nodes following anti-
gen exposure, enhancing their tolerogenic potential.
Loading immature DCs with either native or syn-
thetic peptides or whole antigens may also promote
antigen-specific tolerance through induction of regula-
tory lymphocytes. This strategy addresses multiple auto-
antigens and/or epitopes within a target antigen(s).
Thus, the goal is conditional presentation of self-
antigenic epitopes by DCs to yield Treg induction.
Using the entire antigen affords presentation of a broad-
er repertoire of peptides selected by relevant MHC al-
leles, and potentially avoids artificial epitope(s)
selection. In this respect, preloading microparticles
containing antigen might facilitate DC uptake and
favor tolerogenic phenotypes. Of note, early studies
in which rodents were vaccinated with autoantigen-
loaded DCs demonstrated antigen-specific, durable,
and effective tolerance. These principles have been
applied in human trials of T1D.42 Advantages may
also emerge from strategies in which DCs are al-
lowed to antigen-load in situ.
Small phase I clinical trials exploring DC vaccines
in autoimmune disease have largely focused on T1D
or rheumatoid arthritis. Evidence to date suggests that
tolerizing DC therapies are safe. However, larger trials
will be required to more thoroughly assess safety and
efficacy. Despite the great interest in further assessing
DC vaccines in the prevention, modulation, and cur-
ing of autoimmune diseases, key questions remain.
These include optimization of DC dosing, vaccina-
tion frequency (e.g., boosting), route of administra-
tion, and identification or validation of biomarkers
for assessing therapeutic efficacy.
NMO/SD appears to represent an ideal disease for
DC therapy because a dominant and T cell–restricted
autoantigen (AQP4) has been identified. If successful,
this approach should be used as early in the disease
course as is possible. The rationale for this strategy is
to prevent or ameliorate the expansion of inflamma-
tory AQP4-restricted or other antigen-restricted
T lymphocytes, thereby minimizing broader tissue
injury. In addition, such early intervention could in
concept minimize the potential for antigen spreading
or reversal of antigenic ignorance.
Antigen-coupled presentation. Antigen-specific toleriza-
tion in animal models of disease has been pursued by
a number of laboratory groups. Among these models
are those for experimental autoimmune encephalo-
myelitis (EAE), Theiler virus–induced encephalitis,
tolerance to organ transplantation, and therapy
for severe allergy.6,45–50 Use of peptide-coupled or
chemically fixed antigen-presenting cells (APCs) by
Miller et al.6 has been one strategy. Here, unmodified
splenocytes are pulsed in vitro with a disease-relevant
autoantigen(s), together with a coupling agent. The
host is immunized using these cells, with the goal of
inducing tolerance to a target autoantigen(s). This
approach was effective in reducing disease activity
in a model of relapsing-remitting EAE in SJL
Neurology: Neuroimmunology & Neuroinflammation 5
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mice.45,47 The strategy may also be attractive as
prophylaxis for allotransplantation and the attenuation
of alloreactive immune responses.51 Key advantages of
this approach may include: (1) extensive experience in
EAE and other autoimmune disease models; (2) realistic
potential for targeting multiple autoantigens; (3)
acceptable safety profiles in preclinical studies; (4) an
apparent absence of epitope spreading; and (5) positive
preliminary evidence for efficacy.45 These attributes
provide a strong rationale for applying this approach to
individuals with antigenically characterized autoimmune
diseases such as NMO/SD.
This strategy has been translated to human trials
using unaltered autologous peripheral blood mono-
nuclear cells (PBMCs) as APCs following their isola-
tion by therapeutic leukapheresis.52 In MS, isolated
cells are first pulsed in vitro with a mixture of immu-
nodominant myelin peptides that are identified as
targets of the high-avidity myelin-specific T cell
response.53 A phase I trial was conducted in which
patients received graded dosages of peptide-coupled
and fixed autologous PBMCs.52 Results suggested this
approach was well tolerated, and induced neither
immune reactivity to myelin peptides nor triggered
disease relapses. Rather, the data demonstrated that
the abundance of myelin-reactive T cells was substan-
tially reduced.52 Several putative mechanisms of
action have been attributed to this strategy. First,
APC presentation of cross-linked peptide(s) can lead
to anergy and/or functional silencing of T cells result-
ing from inadequate second-signaling.49,54 Here, the
dominant mechanisms are most likely related to T
cell recognition of peptide-coupled antigen com-
plexes. In this scenario, T cells and/or APCs undergo
apoptosis and are phagocytosed by a special subset of
immature DCs or macrophages in the splenic mar-
ginal zone.45,49,50 These immature DCs/macrophages
can present an autoantigen peptide(s) in a tolerogenic
manner (e.g., IL-10) to pathogenic, autoreactive
T cells. Each of these pathways might help dampen
autoimmunity. Induction of Tregs is also likely critical
in suppressing autoreactivity.45 Tolerization with
peptide-coupled, fixed PBMCs undergoing apoptosis
in vivo does not lead to the induction of anti-DNA
autoantibodies.55 The relevant mechanism(s) involved
in this immune tolerizing strategy and how it might be
applied to human diseases require further study.
Despite promising results in animals, human
studies have been limited to demonstrating that the
abundance of myelin-specific T cells is substantially
reduced52; however, this phase I study was not designed
to elucidate specific mechanisms of action. The above
tolerization approach with AQP4-coupled fixed APCs
could, in theory, be readily adapted to NMO/SD.
Moreover, epitope spreading can occur in this disease56
and may be attenuated by this strategy (reviewed in
reference 57). Thus, tolerization with the entire
AQP4 holoprotein or derivative immunodominant
peptides may dampen autoreactivity against AQP4
and secondary autoantigen targets, providing clinical
benefit. Naturally, technical challenges are likely to arise
in these therapeutic strategies and their approach to the
clinic. Moreover, specific biomarkers for determining
efficacy will be needed to unambiguously inform the
therapeutic benefit. Nonetheless, this approach holds
promise for restoring immune tolerance in NMO/SD
and other autoimmune conditions.
T cell receptor engineering. The ab TcR is the critical
antigen recognition determinant on CD41 and CD81
T cells, conferring both antigen specificity and sensitiv-
ity. TcR diversity results from rearrangement of multi-
ple genes (Figure 2). A key difference from antibodies is
the requirement that ab TcRs bind to peptide ligands
displayed through the APC MHC. This MHC restric-
tion focuses T cell activity against cells that bear the
respective antigen. This mechanism facilitates targeting
to antigen-enriched anatomical sites such as lymph
nodes and infected tissues while effector T cells
promote immune responses against foreign or
endogenous autoantigens. CD41 Tregs suppress these
responses (part II).
Improved understanding of TcR-driven immune
recognition should yield strategies to harness these
cells in treating autoimmune diseases. For example,
autoreactive TcR functions may be redirected to
modulate their disease-propagating phenotypes. By
comparison, ongoing efforts to generate therapeutic
autologous T cells targeting cancer involve engineer-
ing TcRs specific to cancer peptide/class I MHC anti-
gens.58,e1 These cells mature into effector T cells ex
vivo that are then administered to the patient. Initial
attempts involved CD81 T cell clones exhibiting rel-
atively low affinities (KD range 10–100 mM).e1 How-
ever, subsequent engineering has yielded higher
affinity TcRs with KD ranges from 0.1 to 1 mM.
Moreover, TcRs targeting class I antigens do not
require the CD8 coreceptor and are thus capable of
recruiting effector CD41 T cells against cancer cells
expressing their cognate target antigen.e2 Conceiv-
ably, this approach might also prove useful in target-
ing autoreactive cells. To date, TcR engineering has
been accomplished using several methodologies,
including yeast and phage display.e3
Engineered TcRs can be delivered using a variety
of strategies. These include administration as soluble
agents, via gene transfer, or as adoptive T cell thera-
pies. Soluble TcRs will likely require affinities compa-
rable to those of antibodies (KD in nM or pM range),
and formatting as immunoglobulin fusions, bispecific
agents with anti-CD3,e4 or as fusions with immuno-
regulatory molecules such as cytokines.e5 A high-
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affinity TcR against a class II MHC fused to IL-10
has been developed as a means for downregulating
autoimmune responses.e6 Optimizing the tissue tar-
geting of these constructs remains challenging.
Adoptive T cell transfer of enriched Tregs has also
been used as a method of antigen-specific toleriza-
tion.e7,e8 Yet, optimal delivery of antigen-specific, sta-
ble Tregs remains to be determined. Moreover, TcR
affinity and specificity of Tregse9 is less well charac-
terized than those of effector T cells. Several studies
have demonstrated that introducing class I–restricted
TcR into Tregs can redirect their specific activities,e10
and that TcRs with KDs of approximately 1 mM may
be of sufficient avidity to drive Treg activity.e11 TcRs
directed against class I targets required lower affinities
than those in effector CD41 T cells that promote
Treg activity.
Opportunities to generate mouse models and ther-
apeutic T cells targeting AQP4 would appear to be
numerous.e12 For example, in a mouse model, an
immunogenic response can be elicited with effector
T cells (CD41 and/or CD81) expressing an AQP4-
specific antibody (scFv)e13 fused to a chimeric antigen
receptor (CAR). Redirection of Tregs to suppress
effector cells could provide greater therapeutic poten-
tial and utilize CARs directed against AQP4. Alter-
natively, conventional TcRs targeting AQP4 peptide/
MHC class I complexes such as human leukocyte
antigen (HLA)-A2 (which are expressed by 40% of
the population) might prove effective. Possible advan-
tages of CARs include their potential use of scFv from
existing monoclonal antibodies.e13 Furthermore, the
same scFv used in effector T cells to initiate patho-
genic responses could instead be engineered to a Treg
phenotype. Here, scFv affinity could be optimized
using single-site complementarity determining re-
gions mutations. Treg signaling and activity would
depend on the CAR signaling domain specificity
and affinity, as well as density of AQP4 displayed
on target cells. Animal models that more precisely
recapitulate human disease would represent signifi-
cant advances toward these goals.
The TcR approach offers potential advantage over
scFv/CAR, including direct targeting of Treg activity
to class I–bearing tissues and regional lymph nodes,
where AQP4 might be cross-presented by MHC.
Ostensibly, this strategy might arrest or reverse
cross-presentation of AQP4 antigens by class II
MHC, which may occur early in the development
of NMO/SD.e14 If so, this approach may also mitigate
epitope spreading. The generation of TcRs against
AQP4 peptides that bind to HLA-A2 would be rela-
tively straightforward, given the extensive knowledge
of its binding motifs and the likelihood that AQP4
contains cognate epitopes.e15 The TcR affinity in this
scenario may prove inadequate, but such limitations
might be overcome through the generation of CAR
mutants.
AQP4 antigen–specific approaches must address
issues well beyond TcR and CAR affinity. These
include untoward conversion of Tregs to pathogenic
phenotypes such as those exhibiting either Th1 or
Th17 paradigms,e16 accurate tissue targeting, and pro-
motion of memory and stability.e17,e18 It is possible
that the same tolerance checkpoints currently being
considered for rapid deletion of undesirable T cells
transferred in cancer could be applied to NMO/SD.
SUMMARY AND PROSPECTUS: PART I Immune
tolerization attempts to restore central or peripheral tol-
erance, thereby suppressing autoimmune diseases. There
is reason for optimism that this approach might offer
substantial clinical benefit to individuals with NMO/
SD. DNA vaccination, T cell vaccination, tolerogenic
DCs, and peptide-coupling strategies have advanced
to clinic trials. Other promising approaches (e.g.,
CAR-based or Treg-based therapeutics) are in earlier
developmental stages in autoimmune diseases. Yet,
defining target cell lineages to yield durable efficacy,
and determining stage of disease development optimal
for intervention remain crucial ongoing challenges. Past
failures using similar strategies have provided critical
insights that, despite the complexities of existing and
emerging technologies for promoting tolerance, should
illuminate the pathway forward. If so, such advances in
treatment could benefit individuals with NMO/SD
and other autoimmune diseases, including arresting
disease progression, prolonging intervals to remission,
enabling tissue repair, and ultimately avoiding chronic
immunosuppressive therapy.
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